Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSR149744C for prevention of ventricular arrhythmia-triggered ICD interventions
2004-004799-35Phase 2Completed
- Sponsor
- Sanofi
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of celivarone in ventricular tachycardia (VT), ventricular fibrillation (VF) and arrhythmia (3 arms), sponsored by Sanofi. Primary endpoint: Time to all VT or VF arrhythmia episodes leading to ICD intervention. Started Apr 2005; status: completed.
02
Drugs
celivarone
03
Conditions
ventricular tachycardia (VT)ventricular fibrillation (VF)arrhythmia
Beyond the preview
Go deeper on 2004-004799-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004799-35.